References
Clinical & regulatory references
Primary sources behind the pricing guide, trial summaries, and pharmacy-pathway explainers.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID 35658024.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002. PMID 33567185.
- Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). N Engl J Med. 2015;373(1):11-22. PMID 26132939.
- Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. PMID 34170647.
- U.S. FDA. Compounding and the FDA: Questions and Answers; Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
- U.S. Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations.
Brand names (Mounjaro®, Zepbound®, Ozempic®, Wegovy®, Saxenda®) are trademarks of their respective owners, used for identification only. We are not affiliated with Eli Lilly, Novo Nordisk, the FDA, or the FTC.